Digital Content 
NEWS #PharmaBuzz
28 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/28/3122406/0/en/UroGen-Announces-Publication-of-Phase-3b-Study-Results-Demonstrating-the-Feasibility-of-Home-Instillation-of-ZUSDURI-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-B.html
21 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/21/3118671/0/en/UroGen-Announces-Five-Year-Long-Term-Extension-Study-of-the-OPTIMA-II-Trial-Demonstrates-Long-Term-Durability-of-Response-to-ZUSDURI-in-Patients-with-Low-Grade-Intermediate-Risk-No.html
07 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/07/3110960/0/en/UroGen-Announces-Completion-of-Enrollment-in-the-Phase-3-UTOPIA-Clinical-Trial-of-UGN-103-for-the-Treatment-of-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Can.html
14 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250610841284/en/U.S.-FDA-Approves-UroGens-ZUSDURI-mitomycin-for-Intravesical-Solution-as-the-First-and-Only-Medication-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC
06 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250606792691/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
02 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250602781070/en/UroGen-Presents-uTRACT-Registry-at-ASCO-2025-Annual-Meeting-Designed-to-Study-Real-World-Use-of-JELMYTO-in-Low-Grade-Upper-Tract-Urothelial-Cancer
Share 